Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Magnus Ofstad. In this article, we will summarize the ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen ...

Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

A long-term study shows no survival advantage for a second transplant in relapsed myeloma, challenging traditional treatment ...

Bayesian Capital Management made a big biotech play, grabbing 43,000 shares of Amgen worth over $11 million, making it their ...

The Dow Jones Industrial Average is trading down Tuesday afternoon with shares of Merck and Amgen seeing the biggest declines for the blue-chip average.

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

In April 2025, Incyte Corporation announced a study will be conducted to compare the efficacy of axatilimab versus placebo in ...